Safety · Participants with chronic cognitive impairment in traumatic brain injury
1 finding from 1 review
Perinatal mortality (stillbirth ‐ death of fetus prior to birth; neonatal death ‐ death within the first 28 days of birth; or infant death ‐ death after the first 28 days) · pregnant women with a term suspected compromised baby
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): anemia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): anemia Grades 3 or 4 according… compared with best available therapy (low certainty).
1 finding from 1 review
Intervention not reported
Fetal, neonatal and infant death · Women in preterm labour
It is very uncertain whether the intervention changes fetal, neonatal and infant death (very low certainty).
1 finding from 1 review
Fetal or neonatal mortality · women during pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fetal or neonatal mortality · women during pregnancy
Universal screening showed no clear difference in fetal and neonatal death compared with case finding (moderate certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
1 study · 101 participants
GRADE not reported
Live birth rate Live fetus delivered beyond 20 completed weeks' gestation · women with anovulatory infertility undergoing ovulation induction with clomiphene citrate
Human chorionic gonadotrophin showed no clear difference in live birth rate Live fetus delivered beyond 20 completed weeks'… compared with no ovulation trigger (low certainty).
1 finding from 1 review
OR 0.97 [0.52, 1.83]
305 participants
Low
Safety assessments ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Safety of rTMS: Frequency of rTMS side effects (values are percentages) self‐reported questionnaire · participants with panic disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms.
1 study · 50 participants
GRADE not reported
Adverse events and drug reactions · anemia in patients with rheumatoid arthritis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
Very low
Intervention not reported
All cause fetal mortality · pregnant women at term.
1 finding from 1 review